Department of Radiology, Seoul National University College of Medicine, Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea.
Korean J Radiol. 2010 Jan-Feb;11(1):69-74. doi: 10.3348/kjr.2010.11.1.69. Epub 2009 Dec 28.
The objective of this study was to determine the sequential CT findings of controlled hepatocellular carcinoma (HCC) with main portal vein (MPV) thrombosis with the use of transcatheter arterial chemoembolization and additional intra-arterial cisplatin infusion.
From January 2004 to September 2006, 138 patients with HCC invading MPV were referred to the angiography unit of our institution for chemoembolization and additional intra-arterial cisplatin infusion. Until August 2008, seven (5%) of 138 patients were followed-up and found not to have tumor recurrence. CT scans were retrospectively reviewed by two radiologists, focusing on the following parameters: the extent of portal vein thrombosis, the diameter of the affected portal vein, and enhancement of portal vein thrombosis.
THE EXTENT OF PORTAL VEIN THROMBOSIS AT THE INITIAL PRESENTATION WAS VARIABLE: left portal vein (LPV) and MPV (n = 1), right portal vein (RPV) and MPV (n = 3), as well as RPV, LPV and MPV (n = 3). The extent and diameter of the affected portal vein decreased during follow-up examinations. In addition, the degree of enhancement for tumor thrombi and serum alpha-feto-protein levels decreased after the transcatheter arterial chemoembolization. Portal vein thrombosis was found to be completely resolved in one patient, whereas residual thrombus without viability was persistent in six patients.
If chemoembolization is effective in patients with HCC that invades the portal vein, the extent and enhancement of portal vein thrombosis is reduced, but residual thrombosis frequently persists for months or years, without evidence of a viable tumor.
本研究旨在通过经导管动脉化疗栓塞术和额外的动脉内顺铂输注,确定伴有主门静脉(MPV)血栓形成的可控性肝细胞癌(HCC)的连续 CT 表现。
自 2004 年 1 月至 2006 年 9 月,138 例 HCC 侵犯 MPV 的患者被转诊至我们机构的血管造影科进行化疗栓塞和额外的动脉内顺铂输注。直到 2008 年 8 月,对 138 例患者中的 7 例(5%)进行了随访,发现他们没有肿瘤复发。两位放射科医生对 CT 扫描进行了回顾性分析,重点关注以下参数:门静脉血栓形成的程度、受影响门静脉的直径以及门静脉血栓形成的增强程度。
初始表现时门静脉血栓形成的程度各不相同:左门静脉(LPV)和 MPV(n=1)、右门静脉(RPV)和 MPV(n=3)以及 RPV、LPV 和 MPV(n=3)。在随访检查中,受影响门静脉的程度和直径减小。此外,肿瘤血栓和血清甲胎蛋白水平的增强程度在经导管动脉化疗栓塞后降低。在一名患者中发现门静脉血栓完全溶解,而在六名患者中持续存在无活力的残余血栓。
如果化疗栓塞对侵犯门静脉的 HCC 患者有效,门静脉血栓形成的程度和增强程度会降低,但残余血栓通常会持续数月或数年,没有存活肿瘤的证据。